(Press-News.org) Insilico Medicine has licensed TaiGen Biotechnology exclusive rights in the Greater China area to develop, commercialize, and sub-license ISM4808, an AI-driven potential best-in-class oral PHD inhibitor with IND clearance granted in 2023.
The partnership combines Insilico’s generative AI discovery platform with TaiGen’s regional clinical and commercial expertise to accelerate the development of ISM4808 for the treatment of Anemia of Chronic Kidney Disease (CKD).
Shanghai and Taipei, December 12, 2025 --- Insilico Medicine (“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, and TaiGen Biotechnology, a listed discovery-based and market-focused pharmaceutical company, as well as TaiGen Biopharmaceuticals, its wholly-owned Beijing subsidiary (both referred to as “TaiGen”), today announced an exclusive pipeline out-licensing collaboration.
Under the terms of the agreement, TaiGen was granted the exclusive rights for further development, commercialization and sub-licensing in the Greater China area, including Mainland China, Hong Kong, Macau, and Taiwan, of ISM4808 the PHD inhibitor and its related forms and structures. In return, Insilico is eligible for payments including one-time upfront, development and sales-based milestone payments, as well as tiered royalties on net sales, with a total size of two-digit million dollars.
As research indicated, CKD accounts for over 1.5 million deaths annually, and more than one in seven people with kidney disease have anemia, due to less Erythropoietin (EPO)—a hormone that signals bone marrow to make red blood cells, and shorter lifespans of red blood cells. However, anemia cannot be totally cured, and current treatments mainly focus on the relief of symptoms including fatigue, shortness of breath, body aches, dizziness/fainting, hoping to improve the quality of life.
Nominated in 2022 as a potential best-in-class PHD inhibitor, ISM4808 targets the Nobel-winning HIF‑α pathway for the treatment of CKD-related anemia, through EPO induction and iron utilization improvement for better blood cell replacement. Notably, the novel structure of ISM4808 was empowered by Insilico’s proprietary Chemistry42 engine, and was designed, synthesized, and tested within a 12‑month window, prior to candidate nomination. In January 2024, the discovery and development journey of ISM4808 series was published in the Journal of Medicinal Chemistry, highlighting the novelty and high efficiency of Insilico’s AI-driven drug R&D workflow.
In preclinical studies, ISM4808 showed compelling potency across in vitro and in vivo assays, with lower effective doses in CKD rat models; promising oral drug-like properties featuring favorable in vitro ADME and promising pharmacokinetic (PK) profiles across animal models; and a safety profile characterized by higher maximum tolerated doses and broad safety margins. The program received IND clearance from the CDE in China in 2023.
“We are delighted to collaborate with Taigen Biotech,” said Feng Ren, PhD, Co-CEO and CSO of Insilico Medicine. “Powered by AI, Insilico has efficiently nominated two novel PHD inhibitors for different indications. ISM5411, a gut-restricted molecule for inflammatory bowel disease, has completed two Phase I trials, and demonstrated a favorable safety profile, further strengthened our confidence in PHD-targeting programs. We are pleased that the other molecule targeting the same target but with systematic exposure, ISM4808, will be advanced by our partner Taigen, a well-established biopharma company. I believe Taigen’s strong drug development capabilities and clinical resources will help accelerate the program and bring AI-driven therapies to patients worldwide sooner.”
“We are pleased to enter this strategic partnership with Insilico Medicine. The innovation Insilico brings through its generative AI platform is truly impressive.” said Kuo-Lung Huang, Chairman of TaiGen Biotechnology. “With over a million dialysis patients in Mainland China, the PHD inhibitor market is experiencing explosive growth, having surged from approximately 50 million RMB to 2.45 billion RMB in just 5 years. As oral drugs progressively replace traditional injectables, TaiGen is dedicated to advancing this innovative program to meet the urgent clinical need for convenient and compliant therapies.”
About Insilico Medicine
Insilico Medicine, a leading and global AI-driven biotech company, utilizes its proprietary Pharma.AI platform and cutting-stage automated laboratory to accelerate drug discovery and advance innovations in life sciences research. By integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico is delivering innovative drug solutions for unmet needs including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. Additionally, Insilico extends the reach of Pharma.AI across diverse industries, such as advanced materials, agriculture, nutritional products and veterinary medicine. For more information, please visit www.insilico.com.
About TaiGen Biotechnology
Founded in 2001 and listed on the Taiwan OTC Market in 2014, TaiGen Biotechnology is a fully integrated pharmaceutical company focused on innovative small-molecule drugs, particularly anti-infectives. The company has expertise in drug discovery, development, regulatory approval, and multi-country clinical trials, with experience in overseas licensing. Its flagship antibiotic, Taigexyn® (Nemonoxacin), is approved in Taiwan, China, and Russia, while the influenza antiviral TG-1000 has completed Phase III trials and filed an NDA in China.
END
Insilico Medicine and Taigen achieves license agreement to develop and commercialize AI-driven PHD inhibitor for anemia of Chronic Kidney Disease (CKD)
2025-12-11
ELSE PRESS RELEASES FROM THIS DATE:
Exploring dominant endophytic Pleosporales in grasses: New taxonomic insights in the suborder Massarineae
2025-12-11
A research team led by Professor Chulong Zhang at the College of Agriculture and Biotechnology, Zhejiang University, China, investigated dominant endophytic fungi of the order Pleosporales isolated from Poaceae plants collected in Yunnan, Zhejiang, and Inner Mongolia, China. The study, published in Mycology, combined multi-locus phylogenetic analyses with morphological observations to resolve taxonomy and species limits among key pleosporalean endophytes of grasses.
The analysis confirmed that the family Didymosphaeriaceae forms a strongly supported monophyletic group. Within this lineage, the researchers identified multiple well-supported clades corresponding ...
Comparative transcriptomic analysis of human maxillary and mandibular tooth germs reveals discrepancies in gene expression patterns
2025-12-11
The interaction between genetics and tissue environment shapes how individual teeth form in different regions of the jaw. While most experimental studies have focused on mandibular (lower jaw) teeth, little was known about how human maxillary (upper jaw) and mandibular teeth diverge at the molecular level during early development.
In a new study published in Oral Science and Homeostatic Medicine, a collaborative team from Beijing Stomatological Hospital, Capital Medical University, and Peking University School and Hospital of Stomatology performed a RNA-sequencing analysis of human fetal tooth germs at the cap stage (11–12 post-conception ...
Scientists detect atmosphere on molten rocky exoplanet - study
2025-12-11
Researchers using NASA’s James Webb Space Telescope have detected the strongest evidence yet for an atmosphere on a rocky planet outside our solar system.
Observations of the ultra-hot super-Earth TOI-561 b suggest the exoplanet is surrounded by a thick blanket of gases above a global magma ocean.
Publishing their findings today (11 Dec) in The Astrophysical Journal Letters, researchers say that the results help to explain the planet’s unusually low density and challenge the prevailing wisdom that relatively small planets so close ...
Chip-scale magnetometer uses light for high-precision magnetic sensing
2025-12-11
WASHINGTON — Researchers have developed a precision magnetometer based on a special material that changes optical properties in response to a magnetic field. The device, which is integrated onto a chip, could benefit space missions, navigation and biomedical applications.
High-precision magnetometers are used to measure the strength and direction of magnetic fields for various applications. However, many of today’s magnetometers must operate at extremely low temperatures — close to 0 kelvin — or require relatively large and heavy apparatus, which significantly restricts their practicality.
“Our device operates at room temperature and can be fully integrated ...
Illinois Tech biomedical engineering professor Philip R. Troyk elected as Fellow of the National Academy of Inventors
2025-12-11
CHICAGO—December 11, 2025—Philip R. Troyk, director of the Pritzker Institute of Biomedical Science and Engineering at Illinois Institute of Technology (Illinois Tech), has been elected a 2025 fellow of the National Academy of Inventors (NAI). The NAI Fellowship is the highest professional distinction awarded solely to inventors, and Troyk is one of 169 inventors from the United States selected for this distinguished honor this year.
“As an Illinois Tech faculty member, I am pleased to receive this honor and hope ...
The National Academy of Inventors welcomes 2025 Class of Fellows
2025-12-11
The National Academy of Inventors (NAI) has elected the newest class of Fellows, naming 169 U.S. distinguished academic and institutional inventors and 16 International Fellows to the 2025 cohort. Explore the full list of 2025 Fellows here.
NAI Fellowship is the highest professional distinction awarded solely to inventors. Together, the 2025 class hold more than 5,300 U.S. patents and include recipients of the Nobel Prize, the National Medals of Science and Technology & Innovation, and members of the National Academies of Sciences, Engineering, and Medicine, among others. This year’s 169 U.S. Fellows represent ...
Multi-scale modelling framework predicts mechanical responses of Fe–Cr–Al alloys across composition and processing conditions
2025-12-11
A new study published in AI Materials presents a comprehensive multi-scale computational framework capable of predicting the mechanical responses of Fe–Cr–Al alloys while incorporating both solid-solution effects and processing-induced microstructural evolution. By coupling Molecular Dynamics (MD), Phase-Field Method (PFM), and Finite Element Method (FEM) through a temperature-dependent crystal plasticity model, the work provides a pathway for quantitatively linking composition, microstructure, and mechanical performance within the broader context of the Materials Genome Initiative.
Why This Matters
Fe–Cr–Al alloys are among the leading candidates for accident-tolerant ...
Preoperative radiation may improve antitumor immune response in most common form of breast cancer
2025-12-11
SAN ANTONIO – Preoperative radiation improved T-cell infiltration (TCI) in patients with hormone receptor (HR)-positive, HER2-negative breast cancer when administered in combination with pembrolizumab (Keytruda) and chemotherapy and led to improved treatment responses prior to surgery, according to the results of the phase II P-RAD clinical trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December 9-12, 2025.
“Many patients with HR-positive, HER2-negative breast cancer—the most common type of breast cancer—experience late recurrences, and there is a critical need to improve ...
Breast MRI may be safely omitted from diagnostic workup in certain patients with early-stage, HR-negative breast cancer
2025-12-11
SAN ANTONIO – Patients with stage 1 or 2, hormone receptor (HR)-negative breast cancer had similar five-year rates of locoregional recurrence whether or not they underwent preoperative breast magnetic resonance imaging (MRI) in addition to diagnostic mammography to determine the extent of their cancer, according to results from the phase III Alliance A011104/ACRIN 6694 clinical trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December 9-12, 2025.
Breast MRI is commonly included as part of the diagnostic workup of breast cancer ...
Sentinel lymph node biopsy may be safely omitted in some patients with early-stage breast cancer
2025-12-11
SAN ANTONIO – Skipping sentinel lymph node biopsy (SLNB) in patients with clinically node-negative, hormonal receptor (HR)-positive, HER2-negative early-stage breast cancer did not compromise regional control or survival after a median five years of follow-up, according to results from the BOOG 2013-08 phase III clinical trial, presented at the San Antonio Breast Cancer Symposium (SABCS), held December 9-12, 2025.
“Over the past two decades, breast cancer care has shifted toward minimizing invasiveness while preserving oncologic safety,” said Marjolein Smidt, MD, PhD, presenter of this study and professor at the Maastricht University Medical Center ...